Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain. - Wikidata - wikimedia - TriplyDB

Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain.

Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain.

http://www.wikidata.org/entity/Q34568391

about

Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics Fusion to a highly stable consensus albumin binding domain allows for tunable pharmacokinetics The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy Engineering of bispecific affinity proteins with high affinity for ERBB2 and adaptable binding to albumin Engineering bispecificity into a single albumin-binding domain.Bacterial display in combinatorial protein engineering.In vivo targeting of HER2-positive tumor using 2-helix affibody molecules.Selection of nanobodies that target human neonatal Fc receptor.Repeated acetylcholine receptor antibody-concentrations and association to clinical myasthenia gravis development.Development and characterization of small bispecific albumin-binding domains with high affinity for ErbB3.Engineered antibody variable and constant domains as therapeutic candidates.Novel exenatide analogs with peptidic albumin binding domains: potent anti-diabetic agents with extended duration of action The albumin-binding domain as a scaffold for protein engineering.Genetically engineered humanized mouse models for preclinical antibody studies.A truncated and dimeric format of an Affibody library on bacteria enables FACS-mediated isolation of amyloid-beta aggregation inhibitors with subnanomolar affinity.Albumin-binding domain conjugate for near-infrared fluorescence lymphatic imaging.Monoclonal antibodies directed against human FcRn and their applications.Protease substrate profiling using bacterial display of self-blocking affinity proteins and flow-cytometric sorting.Absorption, distribution, metabolism, and excretion (ADME) studies of biotherapeutics for autoimmune and inflammatory conditions.Engineering neonatal Fc receptor-mediated recycling and transcytosis in recombinant proteins by short terminal peptide extensions.A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance.Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial.Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding.Evaluation of an Albumin-Binding Domain Protein Fused to Recombinant Human IL-2 and Its Effects on the Bioactivity and Serum Half-Life of the Cytokine.In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin-binding therapeutic affibody construct.Candidate antibody-based therapeutics against HIV-1.Design and evaluation of radiolabeled tracers for tumor imaging.Fatty Acid-Modified Gapmer Antisense Oligonucleotide and Serum Albumin Constructs for Pharmacokinetic Modulation.Novel affinity binders for neutralization of vascular endothelial growth factor (VEGF) signaling.Engineering of a bispecific affibody molecule towards HER2 and HER3 by addition of an albumin-binding domain allows for affinity purification and in vivo half-life extension.Recent advances in (therapeutic protein) drug development.Extending the half-life of a fab fragment through generation of a humanized anti-human serum albumin Fv domain: An investigation into the correlation between affinity and serum half-life.Dissection of the neonatal Fc receptor (FcRn)-albumin interface using mutagenesis and anti-FcRn albumin-blocking antibodies Pharmacokinetics and mechanisms of plasma removal of hemoglobin-based oxygen carriers.TAT-HSA-α-MSH fusion protein with extended half-life inhibits tumor necrosis factor-α in brain inflammation of mice.Oral delivery of anti-MDM2 inhibitor SP141-loaded FcRn-targeted nanoparticles to treat breast cancer and metastasis.Therapeutic impact of human serum albumin-thioredoxin fusion protein on influenza virus-induced lung injury mice.Interaction with both domain I and III of albumin is required for optimal pH-dependent binding to the neonatal Fc receptor (FcRn).

P2860

Q26801319-179853A2-DB5C-4CD8-911C-ACBC6975658F Q27027238-2394F54C-1AA7-488A-AE24-0B3E82B387C9 Q27701821-BE3ABD6D-E892-420D-AD2F-BCA952F253D3 Q28257521-C4D542D5-C275-40D9-84B9-EF0F2344254A Q28541561-6B21562B-FF23-46C1-851C-A39E10F33F4D Q31032588-614F029B-BD98-4232-8AD5-863AF77D6B42 Q33970172-8E69B680-E6B6-4AC5-9BF8-AAFAFE036C1F Q34231627-F0798099-B629-44A2-AB86-FB9557D272F2 Q34560808-460F2E85-29C1-47A0-AC54-7D0721DF7ABB Q34612356-FFB312DC-50A8-47F6-8F54-565D7D29E540 Q34752052-13C61399-91EF-46BC-955D-375A165980C2 Q35044156-7333B021-F79F-4BF2-8F5A-DC26025BF4BF Q35087618-3C8214A0-1709-4CFA-89BE-A99D8153B963 Q35136577-EA1F2BF6-8D69-4E3D-B824-E0DA6E124DBB Q35552397-F5D9960E-7A2B-4107-9372-F5D608FCF1EE Q35694115-E7A1A642-CF99-47B8-A6F9-F8BB49C588CE Q35942344-27606038-D96E-49E2-AC8C-FCDBE20FB23A Q35992498-95DA6BBC-84BA-4779-B7D6-154F9A15E515 Q36174822-E95E6977-E430-494E-965A-BB96CCDCC2BE Q36331552-E498F04C-FB20-44E4-A64C-4BCAD645FBDA Q36342738-FE2A3719-A9D8-4249-8C40-F2A19255448B Q36610788-306B1735-02BA-47C9-9860-C6FB80DCAEC2 Q36780134-D0BE6B0B-4460-488A-A3DC-4E97F13C05F3 Q37138332-FA2D27CD-B077-4511-9F80-7E9BD95DFC4F Q37327316-851F430A-6581-4DE4-A252-E753F42EE789 Q37611373-79A6DD47-5297-4245-A8B7-72BB91B11470 Q37660979-A263033A-2DB7-4EED-915F-7252038B6D69 Q37998496-F8D083D3-0D84-4E0F-A765-573B128A93F4 Q38137253-351D86CC-10D4-45DB-A908-5AD533D84B45 Q38287887-98B382FE-1FF1-4A36-8FD8-BE60E50A5237 Q38820756-F7478266-AFB3-42F8-95F9-07DE63807D57 Q39010656-E0FA9825-048D-431C-AACB-9B0656539908 Q39148639-3041F180-75DD-4A0B-956E-4E4BC7034D83 Q39675238-DFEC570E-DCEE-45C9-BB83-460E402D131A Q40756807-74115993-CC5B-4CAD-8729-015FF470D368 Q40890012-580122A4-DB05-4692-AB46-2CE8A5BE2F49 Q40948366-A43BD285-E0AB-4426-A012-4C6739677C87 Q41168032-158B488D-31DE-49E0-BAEE-F56C6707D975 Q41653544-5B9586A3-85E4-4545-BFFB-2E4ABF50FF97 Q42551844-171C5734-4A5B-4B49-A8EB-B5659EDCD404

P2860

Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain.

http://www.wikidata.org/entity/Q34568391

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Extending half-life by indirec ...... inimal albumin binding domain.

@ast

Extending half-life by indirec ...... inimal albumin binding domain.

@en

Extending half-life by indirect targeting of the neonatal Fc receptor

@nl

type

label

Extending half-life by indirec ...... inimal albumin binding domain.

@ast

Extending half-life by indirec ...... inimal albumin binding domain.

@en

Extending half-life by indirect targeting of the neonatal Fc receptor

@nl

prefLabel

Extending half-life by indirec ...... inimal albumin binding domain.

@ast

Extending half-life by indirec ...... inimal albumin binding domain.

@en

Extending half-life by indirect targeting of the neonatal Fc receptor

@nl

P1433

Q34568391-D33093F7-3E1C-4C1A-8BCB-2C8708B97A86

P1476

Q34568391-3E78DCE6-1C45-4B58-BD54-B6F8C28E305D

P2093

Q34568391-377E50BA-D353-4FB5-8AC4-BFC1312E386F

Q34568391-3A66D630-9BAD-4F0F-8FF3-24D6F29DDA70

Q34568391-7EE870A1-1F53-441D-B8CD-C6D5380BBB34

Q34568391-8B55B426-3E31-4941-9073-F7154CD113A4

Q34568391-9893EE3E-D68D-4384-9097-4A51A20194B6

Q34568391-B2679831-8FE4-4501-820F-2E17E1154FFA

P2860

Q34568391-04FFD768-08F2-4EB0-B832-9C4127A9EED9

Q34568391-0B72DEE9-076F-44A5-9292-09726E918DCC

Q34568391-0FB779DF-DB78-4EA3-B8DA-18C22B435923

Q34568391-1DE5508D-29DD-48BB-ADBC-AB00873B2332

Q34568391-1F12B241-3B49-4BEB-9CF9-B8DAA020068A

Q34568391-29DFF067-171D-4188-AF64-A7CF3D2F1955

Q34568391-2B26BF12-144A-4042-959A-A6897334CB59

Q34568391-3782D4A3-4FA9-4A66-9A1C-D155F3EF171E

Q34568391-385E1DEE-EF81-46CD-BD37-433DC139ECC7

Q34568391-3ACBDAA3-0DFF-4365-B178-A64D69F551ED

P304

Q34568391-EBFD7450-3759-42A2-8B11-CB461F92A4C9

P31

Q34568391-962947EF-B605-47AD-8DE5-06FCE7A718BA

P356

Q34568391-5605EC54-0E50-48FF-8CD5-320A73761E82

P407

Q34568391-B83F627F-FD55-4853-86B8-CDCBBB7C4B58

P433

Q34568391-1C91C0DC-9FE3-421A-86BA-6A2FAF3846D8

P478

Q34568391-71E2FE13-AC10-4453-A629-1E4433E5D388

P577

Q34568391-A49150C2-D596-4F5C-AB78-5530EB06F5F8

P5875

Q34568391-F8D58C0B-2DC8-43B9-93CB-F1EA8C4EC20F

P698

Q34568391-39D25CD7-5639-4253-9DF5-2BBDBDA43A14

P932

Q34568391-066912E9-27D2-4381-A332-4D8FF5140006

P356

JBC.M110.164848

P1433

Journal of Biological Chemistry

P1476

Extending half-life by indirec ...... inimal albumin binding domain.

@en

P2093

Caroline Ekblad

http://www.w3.org/2001/XMLSchema#string

Jan Terje Andersen

http://www.w3.org/2001/XMLSchema#string

Lars Abrahmsén

http://www.w3.org/2001/XMLSchema#string

Muluneh Bekele Daba

http://www.w3.org/2001/XMLSchema#string

Rikard Pehrson

http://www.w3.org/2001/XMLSchema#string

Vladimir Tolmachev

http://www.w3.org/2001/XMLSchema#string

P2860

The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan

Engineering of a femtomolar affinity binding protein to human serum albumin.

Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity.

Selection and characterization of HER2/neu-binding affibody ligands.

Crystal structure and biological implications of a bacterial albumin binding module in complex with human serum albumin.

Engineering novel binding proteins from nonimmunoglobulin domains.

Tumor imaging using a picomolar affinity HER2 binding affibody molecule.

Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs.

Discovering and improving novel peptide therapeutics.

Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer (review).

P304

5234-5241

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.M110.164848

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

286

http://www.w3.org/2001/XMLSchema#string

P577

2010-12-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49665177

http://www.w3.org/2001/XMLSchema#string

P698

21138843

http://www.w3.org/2001/XMLSchema#string

P932

3037636

http://www.w3.org/2001/XMLSchema#string